2025-523536-39-00Not yet recruitingPhase 1
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Aug 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 5 May 2026
- Start date
- 1 Sept 2026
- Lead sponsor
- TOLREMO therapeutics AG
- Diseases
- Multiple myeloma
- EU CT number
- 2025-523536-39-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 25
- 5 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Not yet recruiting |
| Complejo Asistencial Universitario de Salamanca | Salamanca | Spain | Not yet recruiting |
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spain | Not yet recruiting |
| Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico | Bologna | Italy | Not yet recruiting |
| Ospedale San Raffaele S.r.l. | Milan | Italy | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.